ALNY
Alnylam Pharmaceuticals Inc
256.00$
+2.6%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -18.7% | +14.8% | +90.7% | -16.7% | +193.4% | +124.3% | +71.3% | +22.9% | +76.2% | +23.0% | +65.2% | |
| – | +43.8% | +39.9% | +25.1% | -99.7% | +1,290.8% | +211.4% | +79.6% | +20.5% | +83.9% | +4.2% | +109.4% | |
| – | -18.7% | +14.8% | +90.7% | -18.7% | +166.3% | +113.1% | +69.8% | +23.4% | +74.8% | +26.8% | +57.8% | |
| – | +45.3% | +38.3% | +2.2% | +29.4% | +29.6% | 0.0% | +21.0% | +11.5% | +13.7% | +12.1% | +17.6% | |
| – | +36.1% | +47.4% | +123.1% | +91.8% | +25.3% | +22.8% | +5.5% | +24.2% | +3.2% | +22.6% | +24.1% | |
| – | +43.6% | +39.9% | +25.1% | +50.5% | +27.7% | +9.6% | +13.6% | +17.0% | +8.9% | +16.8% | +20.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +129.0% | +41.8% | +47.3% | +139.1% | +270.9% | -22.2% | +69.3% | +9.1% | -22.3% | +17.0% | +78.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | +4.9% | +210.7% | -74.6% | +512.2% | +61.5% | -1,575.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.